Here it is: bar none, our favorite biotech stock

Fellow Investor,  Last week we featured an early colon cancer detection company listed on the NASDAQ that was trading at under $4 a share. Their product is already on shelves across the EU with FDA approval also in the works. Right after we featured this stock, it shot up to $5.85 and is currently trading at $5.00. Just imagine what could happen with potential FDA approval? We also want to mention that they just had another mega press release announcing a pilot research project related to pancreatic cancer. The growth potential with this news is even greater than last week. There's a big reason why top analysts from HC Wainwright, JonesTrading, and Cantor Fitzgerald have all given this company a buy or overweight rating. They must know something we don't know. Take our word for it, this company is not one to overlook.   Don't underestimate the value of this stock. If you did your research last week, your potential gain could have been 46.62%!   Do your research today. There's still time.   Click here to get the name and symbol right now.         _______________________________________________________ Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.

This email was sent to edwardlorilla1986.paxforex@blogger.com by editor@marketmovingtrends.com CLM LLC c/o MarketMovingTrends, 45 South Park Place, #203, Morristown, NJ 07960 United States   Unsubscribe | Report Spam